A research filter, not a predictor — not financial advice. Grades rank growth stocks on evidence-based quality signals from end-of-day data; they are not buy/sell calls or price forecasts. Always do your own research.
CG Oncology Inc. CGON
Weak (early) (graded 2026-09-02, not re-checked) broader-coverage candidate · CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States.
On FrontierLab's discovery record since 2026-07-23 (10 weeks ago) — when this name first surfaced. (distinct from the snapshot date below)
Auto-graded broader coverage — sourced by an automated screen and graded on default bands, not the sector-calibrated bands the curated screener uses. A "Weak (early)" here is NOT the same bar as a curated grade; these are auto-screened candidates for your own research, shown as of their surface date (2026-09-02), not the curated Frontier signal.
Key quality signals
| Revenue growth (YoY) | — |
|---|---|
| Gross margin | — |
| Gross profits / assets | 0 |
| Rule of 40 | -3025.9 |
| Net margin | -4056.2% |
| Cash runway (months) | 69.1 |
| PEG | — |
| Price / sales | 1074.3 |
Quality checklist
- ✗ Capital efficiency
- ✓ Share dilution — 15.7%
Fundamentals — snapshot as of 2026-09-02
| Stage | Early |
|---|---|
| Share issuance (YoY) | 15.7% · heavy issuance |
| Moat | — |
| TAM | — |
| P/E (trailing) | — |
| EPS (trailing) | $-2.70 |
| Burn multiple | 28.7 |
| Gross-margin trend (pts) | — |
| Cash / assets | 0.95 |
| Net debt / EBITDA | — |
| Statements as of | Q2 FY2026 · filed 2026-08-06 |
Momentum context — a snapshot from 2026-09-02, not current
| Price at surface | $75.86 (as of 2026-09-02) |
|---|---|
| 52-week range | $26.245 – $80.97 |
| % off 52-wk high | -6.3% |
| RSI (14) | 51 |
| Relative volume | 1.2× |
Risk flags
← All broader-coverage names · Curated names → · Open the interactive screener →
Data as of 2026-09-02 (end-of-day). How grades are computed →